• Nephrology
    Nephrologist at Saint Louis hospital in Paris
    Nephrologist at Saint Louis hospital in Paris
    • Chief at Department of Nephrology and Renal Transplantation, Saint-Louis Hospital, Paris, France

    Denis Glotz, Department of Nephrology and Renal Transplantation, Saint-Louis Hospital, Paris, France. Denis Glotz is Chief of the Department of Nephrology and Renal Transplantation, Saint-Louis Hospital in Paris, France. After graduating as MD in 1984, he was granted research fellowship at the Medical Biology Institute, La Jolla, California, USA. He later specialised in nephrology as well as in immunology and became Professor of Nephrology at Université Paris VI and subsequently assumed his current role as Professor of Nephrology at Université Paris VII. Dr Glotz has published over 150 articles in a number of peer-reviewed medical journals including the New England Journal of Medecine, Lancet, British Medical journal, the American Journal of Transplantation, Transplantation and the Journal of the American Society of Nephrology. His main research interests are the characterization of anti-HLA antibodies, the role of IVIg in transplantation, humoral immunity and treatment of antibody-mediated rejection. Dr Glotz sits in the capacity as Head of the INSERM Transplant and Immunology group and is also a member of a number of national and international societies including the American Society of Nephrology, the European Dialysis and Transplantation Association and the French Society of Immunology. He also is an Associate editor of the American journal of transplantation, a member of the Banff foundation and the past President of the French Speaking Transplant Society.

    • General Surgery
    • Transplant Surgeon, James C. Masson Professor of Surgery Research at Mayo Clinic Rochester MN

    I am a Transplant Surgeon at Mayo Clinic, Rochester, MN and the James C. Masson Professor of Surgery Research. Clinically, I perform kidney transplants, pancreas transplants and living donor nephrectomies. Our group has a long-standing interest in kidney transplantation in patients who have antibodies against the donor kidney and have performed more than 500 transplants in this setting. We continue to investigate novel therapies in clinical trials in this area. In research, I have a joint appointment in the Departments of Surgery and Immunology. My main research interests are investigating the causes of late renal allograft loss in order to improve survival and in overcoming antibody barriers to kidney transplantation—especially anti-HLA antibodies. One of my bench laboratories studies antibody secreting plasma cells which we isolate from bone marrow aspirates of transplant recipients. Using a novel in vitro culture system, we study the biology of plasma cells and investigate new therapeutic agents aimed at depleting them. The significance of this research is that antibodies against donor HLA antigens made by normal plasma cells are a major cause of renal allograft loss and constitute a major barrier to successful transplantation. No effective therapy exists that depletes anti-HLA antibodies. A second bench laboratory that I run studies the impact that anti-HLA antibodies have on the kidney transplant. In these studies, we investigate the mechanisms of progressive chronic antibody mediated rejection with a specific interest in why some renal allografts appear to be more resistant to long-term injury. We use a combination of genomics and histology techniques to study mechanisms of injury and accommodation.

  • E. Steve Woodle, MD, FACS, William A. Altemeier Chair in Surgery Professor of Surgery Director, Division of Transplantation Director, Israel Penn International Transplant Tumor Registry Department of Surgery University of Cincinnati College of Medicine. Dr. Woodle received his under graduate degree at Texas A&M University and his medical degree from the University of Texas Medical Branch. He completed fellowships in kidney and pancreas transplantation as well as liver transplantation and hepatobiliary surgery at the University of Chicago, and was an NIH Surgical Research Fellow at both the University of California, Davis, and at the University of Chicago. Dr. Woodle is the second recipient of the William A. Altemeier Chair which is traditionally bestowed on the preeminent researcher in the Department of Surgery at the University Dr. Woodle has authored over 275 scientific articles that have been cited over 7700 times with an h factor of 47. Dr. Woodle has also authored over 20 book chapters in the field of transplantation. Dr. Woodle has been the recipient of NIH basic research grants in immunobiology and has received a Clinician Scientist Research Award from the American Heart Association. He has served on several NIH study sections, and several FDA Advisory Committees and Workshops related to immunosuppressive drug regulatory processes. Dr. Woodle has also served on clinical trial design committees for a number of multicenter studies, and has served as lead investigator in six multicenter Dr. Woodle has made seminal contributions in the areas of immunosuppressive drug development including corticosteroid elimination, and tacrolimus-based therapy for cellular and antibody-mediated rejection. Dr. Woodle introduced two drugs- teplizumab and bortezomib as immunosuppressive agents in the transplant field. Dr. Woodle conceived and reduced to practice the first plasma cell targeted therapy in man. Dr. Woodle also conceived and senior authored the first full publication on kidney exchange in the scientific literature. Through his leadership of the Israel Penn International Transplant Tumor Registry over the past 14 years, he has provided over 4000 consults to the international transplant community free of charge, and his transplantation oncology research has resulted in important contributions regarding malignancies related to organ transplantation. Dr. Woodle is a member of over 30 scientific and professional societies, including the American Surgical Association. He has chaired several committees in the American Society of Transplantation and has served on the Board of Directors of the American Society of Transplantation.

    • General Surgery
    • Assistant Professor in Abdominal Transplant Surgery at Johns Hopkins

    Jacqueline Garonzik Wang, MD PhD Dr. Garonzik Wang will be joining the Johns Hopkins faculty as an assistant professor in Abdominal Transplant Surgery this August after completing her fellowship in Abdominal Transplant Surgery at Washington University this July. She completed her general surgery training at Johns Hopkins in 2014. While at Hopkins, she obtained a PhD in Clinical Investigation, focusing on barriers to living donation. She was instrumental in developing the Live Donor Champion program, and intervention focusing on education and advocacy in efforts to increase living donation. She has numerous other areas of interest including outcomes and health service related research. Jackie is originally from Baltimore, MD and received her bachelors in Public Health in 2002 at the Johns Hopkins University. She subsequently received her medical degree from Emory University in Atlanta, GA in 2006.

Powered by Medstro